VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
QIPTQuipt Home Medical Corp.
$3.65$161M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksQIPTFinancials

Quipt Home Medical Corp. (QIPT) Financials

27Y historyFree accessUpdated daily

Revenue growth remains volatile, swinging from a 55.9% expansion in 2023Q4 to a 6.3% contraction by 2025Q2, while operating margins have failed to stabilize, oscillating between 2.9% and -3.5% over the last ten quarters.

QIPT Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMSep'25Sep'24Sep'23Sep'22Sep'21Sep'20Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10Jun'09Jun'08Jun'07Jun'06Jun'05Jun'04Jun'03Jun'02Jun'01Jun'00Jun'99
Sales/Revenue286.56M245.36M245.91M211.68M139.86M102.35M73.17M61.16M54.58M61.56M96.33M53.41M18.99M3.85M3.96M1.39M38K1.57M2.21M5.89M5.61M4.6M5.97M4.21M3.22M1.95M390.62K0
Revenue Growth %19.78%-0.23%16.17%51.35%36.65%39.88%19.63%12.07%-11.35%-36.09%80.35%181.32%392.63%-2.75%184.9%3560.53%-97.57%-29.23%-62.46%5.04%21.98%-23.03%41.86%30.73%65.66%397.93%--
Cost of Goods Sold24.16M6.05M68.92M57.9M33.21M28.17M34.73M17.06M21.74M17.94M24.2M17.85M6.81M1.33M1.3M563.4K40.67K1.56M2.15M5.13M4.77M4.11M2.88M1.95M1.52M808.63K00
COGS % of Revenue-2.47%28.03%27.35%23.75%27.52%47.46%27.89%39.83%29.14%25.12%33.42%35.85%34.54%32.7%40.5%107.03%99.82%97.33%86.97%84.96%89.28%48.28%46.37%47.14%41.57%--
Gross Profit242.06M239.31M176.99M153.78M106.65M74.18M38.45M44.1M37.75M43.62M49.07M35.56M12.18M2.52M2.67M827.86K-2.67K2.77K58.95K768.44K844.85K492.91K3.09M2.26M1.7M1.14M390.62K0
Gross Margin %84.47%97.53%71.97%72.65%76.25%72.48%52.54%72.11%69.17%70.86%50.94%66.58%64.15%65.46%67.32%59.52%-7.03%0.18%2.66%13.04%15.06%10.72%51.73%53.63%52.86%58.41%100%-
Gross Profit Growth %-35.21%15.09%44.19%43.77%92.94%-12.82%16.82%-13.45%-11.1%37.98%191.96%382.76%-5.43%222.28%31105.99%-196.39%-95.3%-92.33%-9.04%71.4%-84.05%36.83%32.65%49.91%190.82%--
Operating Expenses206.69M181M175.88M150.93M101.92M75.64M39.08M44.1M40.53M56.51M83.19M28.35M9.49M2.31M3.22M1.45M1.69M819.59K555.88K738.11K811.41K825.96K3.46M2.35M1.82M1.48M702.27K0
OpEx % of Revenue-73.77%71.52%71.3%72.87%73.9%53.41%72.11%74.26%91.8%86.37%53.08%49.97%59.82%81.15%104.03%4443.28%52.35%25.13%12.53%14.46%17.96%57.84%55.89%56.64%76.09%179.79%-
Selling, General & Admin74.28M97.48M94.69M82.37M53.82M49.76M25.04M22.46M29.5M28.77M61.02M45.23M5.84M1.75M2.08M1.48M1.53M241.45K508.37K506.01K598.34K653.11K760.11K2.19M1.69M1.35M99.73K35.9K
SG&A % of Revenue-39.73%38.51%38.91%38.48%48.61%34.23%36.72%54.04%46.74%63.34%84.68%30.78%45.36%52.46%106.33%4038.96%15.42%22.98%8.59%10.67%14.2%12.72%51.92%52.45%69.41%25.53%-
Research & Development0000000000000000000000000000
R&D % of Revenue----------------------------
Other Operating Expenses4M83.52M81.18M68.56M48.09M25.88M14.04M21.64M11.03M27.74M22.18M-1.45M3.64M4931.14M-32K153.64K578.14K47.51K232.11K213.07K172.85K2.7M167K135K130K602.54K-35.9K
Operating Income-2.43M-3.82M1.11M5.76M4.73M-1.46M-634.63K-4.63M-5.31M-12.89M-40.61M7.21M2.69M287.78K-548K-651.5K-1.69M-816.82K-497K30.32K-201K-333K-360K-94.35K-122K-344K-66.06K0
Operating Margin %-0.85%-1.56%0.45%2.72%3.38%-1.43%-0.87%-7.56%-9.73%-20.94%-42.16%13.5%14.18%7.47%-13.83%-46.84%-4450.31%-52.18%-22.47%0.51%-3.58%-7.24%-6.03%-2.24%-3.79%-17.69%-16.91%-
Operating Income Growth %--442.87%-80.63%21.68%424.04%-130.06%86.28%12.9%58.8%68.25%-663.06%167.81%835.79%152.51%15.89%61.48%-107.04%-64.35%-1739.07%115.09%39.64%7.5%-281.57%22.67%64.53%-420.76%--
EBITDA46.49M41.83M51.67M45.92M27.77M16.33M13.9M5.92M6.37M-438K-30.02M15.88M4.9M661.98K-250.16K-534.68K-1.68M-783.09K-449.49K266.82K16.27K-155.91K-173.04K72.57K13.54K-213.11K11.81K263
EBITDA Margin %16.22%17.05%21.01%21.69%19.86%15.95%19%9.69%11.68%-0.71%-31.16%29.74%25.8%17.18%-6.31%-38.44%-4430.78%-50.02%-20.32%4.53%0.29%-3.39%-2.9%1.72%0.42%-10.96%3.02%-
EBITDA Growth %-8.48%-19.04%12.52%65.35%70.1%17.42%134.66%-7.02%1554.79%98.54%-289.01%224.21%640.05%364.62%53.21%68.24%-115.01%-74.22%-268.46%1540.24%110.43%9.9%-338.46%435.8%106.36%-1904.02%4399.84%-
D&A (Non-Cash Add-back)48.92M45.66M50.55M40.16M23.04M17.79M14.54M10.55M11.68M12.45M10.59M8.67M2.21M374.21K297.84K116.82K7.42K33.73K47.51K236.5K217.27K177.09K186.96K166.92K135.54K130.89K77.87K263
EBIT-2.57M-3.6M514K4.93M5.01M-7.34M-1.74M-4.78M-4.97M-20.36M-34.96M-15.91M-1.21M296.87K-421.36K-1.58M-1.69M-272.41K-497K30.32K-201.33K-333K-360K-94.35K-121.74K-344K-66.06K0
Net Interest Income-8.26M-6.28M-8.55M-7.24M-1.92M-1.99M-1.86M-3.22M-1.48M-1.13M-847K-1.12M-292.88K-200.44K-127K00-36.01K0000000000
Interest Income376.21K-467K791.49K366.31K00025.68K1.55K0281.42K0000005.79K0000000000
Interest Expense8.64M6.74M9.34M7.61M1.92M1.99M1.86M3.25M1.48M1.13M1.13M1.12M292.88K200.44K127.01K0041.8K0000000000
Other Income/Expense-5.01M-6.52M-7.77M0-1.8M-7.87M-2.94M-4.25M-1.13M-8.59M4.8M-24.24M-4.19M-2.77M28-929.89K96.13K812.89K-998K-78.71K66.08K-51.73K-176K-43.47K4.12K42.21K18.15K3.82K
Pretax Income-9.97M-10.34M-6.65M-2.7M2.94M-9.33M-3.58M-8.87M-6.45M-21.49M-35.81M-17.03M-1.5M-2.47M-548K-1.58M-1.59M-3.93K-1.5M-48.39K-135K-385K-536K-138K-118K-302K-47.91K0
Pretax Margin %-3.48%-4.21%-2.71%-1.28%2.1%-9.11%-4.89%-14.51%-11.81%-34.9%-37.17%-31.88%-7.9%-64.04%-13.83%-113.69%-4197.33%-0.25%-67.59%-0.82%-2.41%-8.37%-8.97%-3.28%-3.66%-15.53%-12.26%-
Income Tax236.38K241K109K85K-1.9M-3.15M128K203.2K100.62K354.69K-8.33M961.69K-97.65K200.44K127.01K913.21K0056.1K-205K156.61K86.28K18K-96.28K38.75K34.66K193.35K37.88K
Effective Tax Rate %-2.37%-2.33%-1.64%-3.15%-64.87%33.82%-3.58%-2.29%-1.56%-1.65%23.26%-5.65%6.51%-8.12%-23.18%-57.75%0%0%-3.75%423.62%-116.01%-22.41%-3.36%69.77%-32.84%-11.48%-403.6%-
Net Income-10.74M-10.7M-6.76M-2.78M4.84M-6.17M-4.57M-5.58M14.51M-19.15M-57.37M-18.32M-1.4M-2.55M-548K-1.58M-1.59M1.26M-1.79M715.84K-292K-710K-624K-41.54K-156K-336K-241.26K-34.05K
Net Margin %-3.75%-4.36%-2.75%-1.32%3.46%-6.03%-6.25%-9.12%26.59%-31.11%-59.56%-34.31%-7.38%-66.07%-13.83%-113.66%-4197.33%80.68%-81.06%12.15%-5.21%-15.44%-10.44%-0.99%-4.84%-17.28%-61.76%-
Net Income Growth %-61.83%-58.23%-142.92%-157.53%178.38%-35.04%18.05%-138.45%175.76%66.62%-213.09%-1206.99%44.94%-364.67%65.34%0.88%-226.28%170.44%-350.48%345.15%58.87%-13.78%-1402.17%73.37%53.57%-39.27%-608.49%-
Net Income (Continuing)-10.22M-10.58M-6.76M-2.78M4.84M-6.17M-3.7M-6.91M-6.55M-21.84M-27.48M-17.99M-1.4M-2.55M-548.37K-1.58M-1.69M-3.93K-1.55M156.59K-208.27K-471.07K-554K-41.54K-156.37K-336.47K-241.26K-34.05K
Discontinued Operations000000-869K1.33M0000000000-241K000000000
Minority Interest12.04M11.7M0000000000000000210.67K000000000
EPS (Diluted)-0.25-0.25-0.16-0.070.13-0.20-0.20-0.270.72-1.02-3.23-1.60-0.22-0.72-0.17-0.51-0.7423.08-28.7811.28-4.16-8.88-18.94-3.57-19.78-66.08-60.76-13.57
EPS Growth %-56.12%-56.25%-128.57%-153.85%165%0%25.93%-137.5%170.59%68.42%-101.88%-627.27%69.44%-323.53%66.67%31.08%-103.21%180.19%-355.14%371.15%53.15%53.12%-430.53%81.95%70.07%-8.76%-347.75%-
EPS (Basic)--0.25-0.16-0.070.14-0.20-0.17-0.270.72-1.02-3.23-1.60-0.22-0.72-0.17-0.51-0.7423.08-55.0212.47-5.09-8.88-18.94-3.57-19.78-66.08-60.76-13.57
Diluted Shares Outstanding43.61M43.29M42.5M39.77M37.22M30.44M22.72M20.71M20.19M18.85M17.76M11.49M6.47M3.43M3.21M3.01M2.15M54.71K62.3K63.47K70.21K79.96K66.23K11.62K7.91K5.09K3.97K2.51K
Basic Shares Outstanding43.61M43.29M42.5M39.77M34.56M30.44M28.05M20.71M20.19M18.85M17.76M11.49M6.47M3.43M3.21M3.01M2.15M54.71K32.58K57.39K57.39K79.96K66.23K11.62K7.91K5.09K3.97K2.51K
Dividend Payout Ratio----------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Regulatory reimbursement and integration

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Inconsistent Revenue Growth Patterns Observed

According to the provided quarterly financial data, QIPT's revenue growth has exhibited significant volatility, swinging from a 55.9% expansion in 2023Q4 to a 6.3% contraction by 2025Q2, suggesting that the company's reliance on inorganic acquisition-led growth may be struggling to maintain consistent organic momentum.

The erratic revenue trajectory indicates that the company's roll-up strategy is not currently yielding the predictable scale benefits typically expected in the DME sector. Investors should monitor whether the recent return to 34% growth in 2026Q1 represents a sustainable turnaround or merely the lumpy impact of recent M&A activity.

Anomalous Gross Margin Volatility Persists

As reported in the company's income statements, gross margins have fluctuated wildly, reaching an extreme 119.5% in 2025Q4 before normalizing to 56.4% in 2026Q1, which raises significant questions regarding the consistency of cost allocation and the underlying unit economics of the respiratory equipment business.

Such extreme variance in gross margin suggests that the company may be inconsistently classifying operational costs, potentially masking the true cost of service delivery. This lack of stability makes it difficult to assess the company's actual pricing power or its ability to defend margins against inflationary pressures in clinical labor.

Operating Leverage Remains Elusive Currently

Based on the reported figures, QIPT has failed to demonstrate consistent operating leverage, with operating margins oscillating between a high of 2.9% and a low of -3.5% over the last ten quarters, indicating that administrative overhead continues to scale in lockstep with or faster than revenue.

The inability to consistently generate positive operating income despite significant revenue scale suggests that the company's 'hub-and-spoke' logistics model may be more capital-intensive than the market appreciates. Without a clear path to operating margin expansion, the business remains vulnerable to any further stagnation in top-line growth.

Persistent Net Losses Cloud Quality

As evidenced by the ten-quarter financial history, QIPT has consistently reported negative net income, with losses reaching as deep as $3.5 million in 2025Q4, a trend that persists despite the company's ongoing efforts to integrate regional acquisitions into a unified national platform.

The recurring nature of these net losses, coupled with ongoing stock-based compensation expenses, suggests that the company is currently prioritizing growth over profitability. Investors should be wary of the potential for continued shareholder dilution if the company remains unable to achieve a sustainable bottom-line inflection point.

Structural Risks to Margin Sustainability

Based on an analysis of the provided data, short-sellers would likely focus on the company's inability to convert high gross margins into positive net income, as well as the potential for future write-downs related to the aggressive accounting of doubtful accounts in the complex DME billing environment.

The reliance on M&A to drive growth, combined with a negative net margin profile, suggests that the company's current business model may be fundamentally over-leveraged. Any regulatory shift in CMS reimbursement rates could exacerbate these existing profitability challenges, potentially leading to a rapid deterioration in the company's liquidity position.

QIPT — Frequently Asked Questions

Quick answers to the most common questions about buying QIPT stock.

What was Quipt Home Medical Corp.'s (QIPT) revenue in 2025?

For fiscal year 2025, Quipt Home Medical Corp. (QIPT) reported total revenue of $245.4M.

Is Quipt Home Medical Corp. (QIPT) profitable?

Quipt Home Medical Corp. (QIPT) reported a net loss of $10.7M for the fiscal year ending 2025.

What is Quipt Home Medical Corp.'s operating profit margin?

Quipt Home Medical Corp. (QIPT) reported an operating income of $-3.8M, resulting in an operating profit margin of -1.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Quipt Home Medical Corp.'s gross profit and gross margin?

Quipt Home Medical Corp. (QIPT) generated $239.3M in gross profit for the year, representing a gross profit margin of 97.5%. This demonstrates the company's core pricing power and production efficiency.